# Anne Osdoit

> Anne Osdoit is a seed investor at Moon Surgical (Paris) backing Medical Device and Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Moon Surgical](https://shizune.co/investors/profile/mastor)
- Location: Paris, France
- Total investments: 7
- Last investment: May 2023
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/anne-osdoit-5812807

Anne Osdoit is a seed investor at Moon Surgical in Paris focused on Medical Device and Health Care. Anne Osdoit is the Chief Executive Officer of Moon Surgical and a Partner at Sofinnova Partners and MD Start. She joined MD Start after spending almost 10 years developing Mauna Kea Technologies, a medical technology French start-up company with global operations, offering a disruptive "optical biopsy" technology. At Mauna KeaTechnologies, Anne held various positions in clinical and regulatory development as well as marketing and sales support. She was also heavily involved in the different financing rounds as well as in the IPO process. She interfaced with the key opinion leaders and has an extensive network in the fields of endoscopy and surgery (digestive, pulmonary, and urological mostly, but not exclusively). Having lived and worked in hospital environments in the USA and in the UK, Anne can translate unmet medical needs into product projects and integrate input from all around the world. Anne is an Advisory Board member of FeetMe (France) and Cardiologs (France). Anne is a trained biomedical engineer from Ecole Polytechnique of Paris, France, and Johns Hopkins University in Baltimore, USA.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 4 | 57% |
| Health Care | 3 | 43% |
| Medical | 2 | 29% |
| Biotechnology | 1 | 14% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 43% |
| Series A | 1 | 14% |
| Series B | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 3 | 43% |
| Israel | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Moon Surgical | MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. | $55.4M | Series B | May 17, 2023 |  |
| Moon Surgical | MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. | $55.4M | Series B | May 17, 2023 |  |
| Moon Surgical | MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. | $31.3M | Series A | Jun 07, 2022 |  |
| Moon Surgical | MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. | $3.4M | Seed | Jul 02, 2020 |  |
| Pi-Cardia | Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes severalseconds, is intended to increase the valve effective orifice area without the need to replace the valve. | $27M | Venture - Series Unknown | Apr 20, 2020 |  |
| Gradient Denervation Technologies | Gradient Denervation Technologies develops a medical device for a transvascular treatment of pulmonary hypertension, based on prior research and intellectual property developed at Stanford University. |  | Seed | Feb 01, 2020 |  |
| HEPTA Medical | HEPTA Medical develops a sensor, embedded into a bronchoscopic or percutaneous ablation catheter, which provides temperature-based feedback. This enables real-time dosing to precisely target and ablates pulmonary nodules, the precursor of lung cancer, without the need for surgery or radiation. |  | Seed | Jun 01, 2019 |  |

7 of 7 investments shown.

## Co-investors
- [Cathay Capital](https://shizune.co/investors/profile/cathaycapital) — VC Fund, 3 deals together
- [GT Healthcare Capital Partners](https://shizune.co/investors/profile/gt-healthcare-capital-partners) — VC Fund, 3 deals together
- [Johnson & Johnson Robotics and Digital Solutions](https://shizune.co/investors/profile/johnson-johnson-innovation) — VC Fund, 3 deals together
- [NVentures](https://shizune.co/investors/profile/nventures-0731) — VC Fund, 2 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 2 deals together
- [MD Start](https://shizune.co/investors/profile/md-start) — VC Fund, 1 deal together

## About Moon Surgical

VC Fund · Paris, France

MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.

2 contacts available at Moon Surgical.

| Name | Title | Profile |
| --- | --- | --- |
| Anne Osdoit | Chief Executive Officer | https://shizune.co/investors/profile/anne-osdoit |
| Jeffery Alvarez | COO | https://shizune.co/investors/profile/jeffery-alvarez |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Anne Osdoit invest in?

Anne Osdoit invests primarily in Medical Device, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Anne Osdoit last invest?

The most recent investment recorded for Anne Osdoit closed in May 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co